BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 25210187)

  • 1. Circulating clinical strains of human parainfluenza virus reveal viral entry requirements for in vivo infection.
    Palmer SG; DeVito I; Jenkins SG; Niewiesk S; Porotto M; Moscona A
    J Virol; 2014 Nov; 88(22):13495-502. PubMed ID: 25210187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adaptation of human parainfluenza virus to airway epithelium reveals fusion properties required for growth in host tissue.
    Palmer SG; Porotto M; Palermo LM; Cunha LF; Greengard O; Moscona A
    mBio; 2012; 3(3):. PubMed ID: 22669629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction between the hemagglutinin-neuraminidase and fusion glycoproteins of human parainfluenza virus type III regulates viral growth in vivo.
    Xu R; Palmer SG; Porotto M; Palermo LM; Niewiesk S; Wilson IA; Moscona A
    mBio; 2013 Oct; 4(5):e00803-13. PubMed ID: 24149514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibiting Human Parainfluenza Virus Infection by Preactivating the Cell Entry Mechanism.
    Bottom-Tanzer SF; Rybkina K; Bell JN; Alabi CA; Mathieu C; Lu M; Biswas S; Vasquez M; Porotto M; Melero JA; Más V; Moscona A
    mBio; 2019 Feb; 10(1):. PubMed ID: 30782664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human parainfluenza virus fusion complex glycoproteins imaged in action on authentic viral surfaces.
    Marcink TC; Wang T; des Georges A; Porotto M; Moscona A
    PLoS Pathog; 2020 Sep; 16(9):e1008883. PubMed ID: 32956394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Electron tomography imaging of surface glycoproteins on human parainfluenza virus 3: association of receptor binding and fusion proteins before receptor engagement.
    Gui L; Jurgens EM; Ebner JL; Porotto M; Moscona A; Lee KK
    mBio; 2015 Feb; 6(1):e02393-14. PubMed ID: 25691596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Viral Entry Properties Required for Fitness in Humans Are Lost through Rapid Genomic Change during Viral Isolation.
    Iketani S; Shean RC; Ferren M; Makhsous N; Aquino DB; des Georges A; Rima B; Mathieu C; Porotto M; Moscona A; Greninger AL
    mBio; 2018 Jul; 9(4):. PubMed ID: 29970463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hijacking the Fusion Complex of Human Parainfluenza Virus as an Antiviral Strategy.
    Marcink TC; Yariv E; Rybkina K; Más V; Bovier FT; des Georges A; Greninger AL; Alabi CA; Porotto M; Ben-Tal N; Moscona A
    mBio; 2020 Feb; 11(1):. PubMed ID: 32047132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Features of Circulating Parainfluenza Virus Required for Growth in Human Airway.
    Palermo LM; Uppal M; Skrabanek L; Zumbo P; Germer S; Toussaint NC; Rima BK; Huey D; Niewiesk S; Porotto M; Moscona A
    mBio; 2016 Mar; 7(2):e00235. PubMed ID: 26980833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of measles virus infection by intranasal delivery of fusion inhibitor peptides.
    Mathieu C; Huey D; Jurgens E; Welsch JC; DeVito I; Talekar A; Horvat B; Niewiesk S; Moscona A; Porotto M
    J Virol; 2015 Jan; 89(2):1143-55. PubMed ID: 25378493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism of fusion triggering by human parainfluenza virus type III: communication between viral glycoproteins during entry.
    Porotto M; Palmer SG; Palermo LM; Moscona A
    J Biol Chem; 2012 Jan; 287(1):778-793. PubMed ID: 22110138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spring-loaded model revisited: paramyxovirus fusion requires engagement of a receptor binding protein beyond initial triggering of the fusion protein.
    Porotto M; Devito I; Palmer SG; Jurgens EM; Yee JL; Yokoyama CC; Pessi A; Moscona A
    J Virol; 2011 Dec; 85(24):12867-80. PubMed ID: 21976650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Vivo Efficacy of Measles Virus Fusion Protein-Derived Peptides Is Modulated by the Properties of Self-Assembly and Membrane Residence.
    Figueira TN; Palermo LM; Veiga AS; Huey D; Alabi CA; Santos NC; Welsch JC; Mathieu C; Horvat B; Niewiesk S; Moscona A; Castanho MARB; Porotto M
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27733647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Third Helical Domain of the Nipah Virus Fusion Glycoprotein Modulates both Early and Late Steps in the Membrane Fusion Cascade.
    Zamora JLR; Ortega V; Johnston GP; Li J; André NM; Monreal IA; Contreras EM; Whittaker GR; Aguilar HC
    J Virol; 2020 Sep; 94(19):. PubMed ID: 32669342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fusion activation through attachment protein stalk domains indicates a conserved core mechanism of paramyxovirus entry into cells.
    Bose S; Song AS; Jardetzky TS; Lamb RA
    J Virol; 2014 Apr; 88(8):3925-41. PubMed ID: 24453369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human parainfluenza virus infection of the airway epithelium: viral hemagglutinin-neuraminidase regulates fusion protein activation and modulates infectivity.
    Palermo LM; Porotto M; Yokoyama CC; Palmer SG; Mungall BA; Greengard O; Niewiesk S; Moscona A
    J Virol; 2009 Jul; 83(13):6900-8. PubMed ID: 19386708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineering Protease-Resistant Peptides to Inhibit Human Parainfluenza Viral Respiratory Infection.
    Outlaw VK; Cheloha RW; Jurgens EM; Bovier FT; Zhu Y; Kreitler DF; Harder O; Niewiesk S; Porotto M; Gellman SH; Moscona A
    J Am Chem Soc; 2021 Apr; 143(15):5958-5966. PubMed ID: 33825470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fusion promotion by a paramyxovirus hemagglutinin-neuraminidase protein: pH modulation of receptor avidity of binding sites I and II.
    Palermo LM; Porotto M; Greengard O; Moscona A
    J Virol; 2007 Sep; 81(17):9152-61. PubMed ID: 17567695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual Inhibition of Human Parainfluenza Type 3 and Respiratory Syncytial Virus Infectivity with a Single Agent.
    Outlaw VK; Bottom-Tanzer S; Kreitler DF; Gellman SH; Porotto M; Moscona A
    J Am Chem Soc; 2019 Aug; 141(32):12648-12656. PubMed ID: 31268705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sendai virus recombinant vaccine expressing hPIV-3 HN or F elicits protective immunity and combines with a second recombinant to prevent hPIV-1, hPIV-3 and RSV infections.
    Zhan X; Slobod KS; Krishnamurthy S; Luque LE; Takimoto T; Jones B; Surman S; Russell CJ; Portner A; Hurwitz JL
    Vaccine; 2008 Jun; 26(27-28):3480-8. PubMed ID: 18499307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.